These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9586692)
1. Differences of HIV envelope protein between HIV-1 and HIV-2: possible relation to the lower virulence of HIV-2. Sekigawa I; Kaneko H; Neoh LP; Takeda-Hirokawa N; Akimoto H; Hishikawa T; Hashimoto H; Hirose S; Yamamoto N; Kaneko Y Viral Immunol; 1998; 11(1):1-8. PubMed ID: 9586692 [No Abstract] [Full Text] [Related]
2. The production of beta-chemokines induced by HIV-2 envelope glycoprotein. Neoh LP; Akimoto H; Kaneko H; Hishikawa T; Hashimoto H; Hirose S; Kaneko Y; Yamamoto N; Sekigawa I AIDS; 1997 Jul; 11(8):1062-3. PubMed ID: 9223745 [No Abstract] [Full Text] [Related]
3. [Effect of HIV envelope glycoprotein on the induction of immune dysregulation in HIV infection]. Sekigawa I; Akimoto H; Kaneko H Nihon Rinsho Meneki Gakkai Kaishi; 1998 Feb; 21(1):11-9. PubMed ID: 9884546 [TBL] [Abstract][Full Text] [Related]
4. Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity. Cavaleiro R; Sousa AE; Loureiro A; Victorino RM AIDS; 2000 Dec; 14(17):2679-86. PubMed ID: 11125886 [TBL] [Abstract][Full Text] [Related]
5. A proposal for immunotherapy of HIV seropositive healthy individuals using an HIV envelope protein devoid of CD4 binding activity. Van Kuyk R; Luciw PA; Gardner MB AIDS Res Hum Retroviruses; 1990 Jul; 6(7):831-4. PubMed ID: 1975193 [No Abstract] [Full Text] [Related]
6. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens. Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590 [TBL] [Abstract][Full Text] [Related]
7. Binding of recombinant HIV-1 and HIV-2 SU glycoproteins to sCD4. Moore JP; Morikawa Y; Jones IM J Acquir Immune Defic Syndr (1988); 1991; 4(4):442-3. PubMed ID: 2007979 [No Abstract] [Full Text] [Related]
8. Idiotypic expression of anti-gp120 antibodies in unrelated human immunodeficiency virus-infected individuals. Février M; Boudet F; Corre JP; Chamaret S; Thèze J; Zouali M J Gen Virol; 1992 Oct; 73 ( Pt 10)():2561-8. PubMed ID: 1383396 [TBL] [Abstract][Full Text] [Related]
9. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911 [No Abstract] [Full Text] [Related]
10. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. Stamatatos L; Lim M; Cheng-Mayer C AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360 [TBL] [Abstract][Full Text] [Related]
11. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425 [No Abstract] [Full Text] [Related]
12. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645 [TBL] [Abstract][Full Text] [Related]
13. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. Neurath AR; Strick N; Li YY; Jiang S AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138 [TBL] [Abstract][Full Text] [Related]
14. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. McBurney SP; Young KR; Ross TM Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011 [TBL] [Abstract][Full Text] [Related]
15. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282 [TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells. Kaneko H; Neoh LP; Takeda N; Akimoto H; Hishikawa T; Hashimoto H; Hirose S; Karaki S; Takiguchi M; Nakauchi H; Kaneko Y; Yamamoto N; Sekigawa I J Virol; 1997 Nov; 71(11):8918-22. PubMed ID: 9343259 [TBL] [Abstract][Full Text] [Related]
17. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. Marcelino JM; Barroso H; Gonçalves F; Silva SM; Novo C; Gomes P; Camacho R; Taveira N J Clin Microbiol; 2006 Feb; 44(2):607-11. PubMed ID: 16455923 [TBL] [Abstract][Full Text] [Related]
18. Stable expression of the human immunodeficiency virus type 1 envelope glycoprotein in transfected L cells. Bird C; Gleeson PA; Ramsay A; Li P; McCluskey J AIDS Res Hum Retroviruses; 1992 Dec; 8(12):1999-2009. PubMed ID: 1493050 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925 [TBL] [Abstract][Full Text] [Related]
20. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Dis Markers; 1991; 9(1):51. PubMed ID: 1742945 [No Abstract] [Full Text] [Related] [Next] [New Search]